Erratum: A roadmap for precision medicine in the epilepsies (The Lancet Neurology (2015) 14(12) (1219–1228)(S1474442215001994)(10.1016/S1474-4422(15)00199-4));A roadmap for precision medicine in the epilepsies

The Lancet Neurology

Volumn 14, Issue 12, 2015, Pages 1219-1228

  Berkovic, S F ^a   Scheffer, I E ^a   Petrou, S ^a   Delanty, N ^b,c   Dixon Salazar, T J ^d   Dlugos, D J ^e,f   Helbig, I ^e,g   Frankel, W N ^h   Goldstein, D B ⁱ   Heinzen, E L ^i,j   Lowenstein, D H ^k   Mefford, H C ^l   Parent, J M ^m   Poduri, A ⁿ   Traynelis, S F ^o  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^c BEAUMONT HOSPITAL   (Ireland)

^d CURE Epilepsy   (United States)

^e CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g UNIVERSITY OF KIEL   (Germany)

^h JACKSON LABORATORY   (United States)

ⁱ Och Spine at New York Presbyterian Hospitals   (United States)

^j NewYork Presbyterian Hospital   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^m UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

ⁿ BOSTON CHILDREN S HOSPITAL   (United States)

^o EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; COHORT ANALYSIS; EPILEPSY; GENE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; GENOME ANALYSIS; HUMAN; MOLECULAR GENETICS; NEXT GENERATION SEQUENCING; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYNAPTIC TRANSMISSION; TRANSLATIONAL RESEARCH; DRUG DEVELOPMENT; GENETICS; MUTATION; PERSONALIZED MEDICINE;

ANTICONVULSIVE AGENT;

ANTICONVULSANTS; DRUG DISCOVERY; EPILEPSY; HUMANS; MUTATION; PRECISION MEDICINE;

EID: 84947046903     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(16)00012-0     Document Type: Erratum

References (114)

1. Moving toward precision medicine. Lancet 2011, 378:1678. The Lancet.
2. Collisson EA, Cho RJ, Gray JW What are we learning from the cancer genome?. Nat Rev Clin Oncol 2012, 9:621-630.
3. Annegers JF, Hauser WA, Anderson VE, Kurland LT The risks of seizure disorders among relatives of patients with childhood onset epilepsy. Neurology 1982, 32:174-179.
4. Corey LA, Berg K, Pellock JM, Solaas MH, Nance WE, DeLorenzo RJ The occurrence of epilepsy and febrile seizures in Virginian and Norwegian twins. Neurology 1991, 41:1433-1436.
5. Berkovic SF, Howell RA, Hay DA, Hopper JL Epilepsies in twins: genetics of the major epilepsy syndromes. Ann Neurol 1998, 43:435-445.
6. Lennox WG, Lennox MA The genetics of epilepsy. Epilepsy and related disorders 1960, vol 1:532-574. Little Brown, Boston, MA.
7. Peljto AL, Barker-Cummings C, Vasoli VM, et al. Familial risk of epilepsy: a population-based study. Brain 2014, 137:795-805.
8. Speed D, O'Brien TJ, Palotie A, et al. Describing the genetic architecture of epilepsy through heritability analysis. Brain 2014, 137:2680-2689.
9. Beck C, Moulard B, Steinlein O, et al. A nonsense mutation in the alpha4 subunit of the nicotinic acetylcholine receptor (CHRNA4) cosegregates with 20q-linked benign neonatal familial convulsions (EBNI). Neurobiol Dis 1994, 1:95-99.
10. Baulac S, Picard F, Herman A, et al. Evidence for digenic inheritance in a family with both febrile convulsions and temporal lobe epilepsy implicating chromosomes 18qter and 1q25-q31. Ann Neurol 2001, 49:786-792.
11. +-channel beta1 subunit gene SCN1B. Nat Genet 1998, 19:366-370.
12. Dibbens LM, Feng HJ, Richards MC, et al. GABRD encoding a protein for extra- or peri-synaptic GABAA receptors is a susceptibility locus for generalized epilepsies. Hum Mol Genet 2004, 13:1315-1319.
13. Moulard B, Guipponi M, Chaigne D, Mouthon D, Buresi C, Malafosse A Identification of a new locus for generalized epilepsy with febrile seizures plus (GEFS+) on chromosome 2q24-q33. Am J Hum Genet 1999, 65:1396-1400.
14. Kalachikov S, Evgrafov O, Ross B, et al. Mutations in LGI1 cause autosomal-dominant partial epilepsy with auditory features. Nat Genet 2002, 30:335-341.
15. Escayg A, MacDonald BT, Meisler MH, et al. Mutations of SCN1A, encoding a neuronal sodium channel, in two families with GEFS+2. Nat Genet 2000, 24:343-345.
16. Baulac S, Gourfinkel-An I, Picard F, et al. A second locus for familial generalized epilepsy with febrile seizures plus maps to chromosome 2q21-q33. Am J Hum Genet 1999, 65:1078-1085.
17. Klepper J, Willemsen M, Verrips A, et al. Autosomal dominant transmission of GLUT1 deficiency. Hum Mol Genet 2001, 10:63-68.
18. Saitsu H, Kato M, Mizuguchi T, et al. De novo mutations in the gene encoding STXBP1 (MUNC18-1) cause early infantile epileptic encephalopathy. Nat Genet 2008, 40:782-788.
19. Claes L, Del-Favero J, Ceulemans B, Lagae L, Van Broeckhoven C, De Jonghe P De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet 2001, 68:1327-1332.
20. Kalscheuer VM, Tao J, Donnelly A, et al. Disruption of the serine/threonine kinase 9 gene causes severe X-linked infantile spasms and mental retardation. Am J Hum Genet 2003, 72:1401-1411.
21. Dibbens LM, Tarpey PS, Hynes K, et al. X-linked protocadherin 19 mutations cause female-limited epilepsy and cognitive impairment. Nat Genet 2008, 40:776-781.
22. Cavalleri GL, Weale ME, Shianna KV, et al. Multicentre search for genetic susceptibility loci in sporadic epilepsy syndrome and seizure types: a case-control study. Lancet Neurol 2007, 6:970-980.
23. Kasperaviciute D, Catarino CB, Heinzen EL, et al. Common genetic variation and susceptibility to partial epilepsies: a genome-wide association study. Brain 2010, 133:2136-2147.
24. Genetic determinants of common epilepsies: a meta-analysis of genome-wide association studies. Lancet Neurol 2014, 13:893-903. International League Against Epilepsy Consortium on Complex Epilepsies.
25. Consortium E, Leu C, de Kovel CG, et al. Genome-wide linkage meta-analysis identifies susceptibility loci at 2q34 and 13q31.3 for genetic generalized epilepsies. Epilepsia 2012, 53:308-318.
26. Consortium E, Consortium EM, Steffens M, et al. Genome-wide association analysis of genetic generalized epilepsies implicates susceptibility loci at 1q43, 2p16.1, 2q22.3 and 17q21.32. Hum Mol Genet 2012, 21:5359-5372.
27. Helbig I, Mefford HC, Sharp AJ, et al. 15q13.3 microdeletions increase risk of idiopathic generalized epilepsy. Nat Genet 2009, 41:160-162.
28. Sharp AJ, Mefford HC, Li K, et al. A recurrent 15q13.3 microdeletion syndrome associated with mental retardation and seizures. Nat Genet 2008, 40:322-328.
29. de Kovel CG, Trucks H, Helbig I, et al. Recurrent microdeletions at 15q11.2 and 16p13.11 predispose to idiopathic generalized epilepsies. Brain 2010, 133:23-32.
30. Heinzen EL, Radtke RA, Urban TJ, et al. Rare deletions at 16p13.11 predispose to a diverse spectrum of sporadic epilepsy syndromes. Am J Hum Genet 2010, 86:707-718.
31. Mefford HC, Muhle H, Ostertag P, et al. Genome-wide copy number variation in epilepsy: novel susceptibility loci in idiopathic generalized and focal epilepsies. PLoS Genet 2010, 6:e1000962.
32. Ben-Shachar S, Lanpher B, German JR, et al. Microdeletion 15q13.3: a locus with incomplete penetrance for autism, mental retardation, and psychiatric disorders. J Med Genet 2009, 46:382-388.
33. Grayton HM, Fernandes C, Rujescu D, Collier DA Copy number variations in neurodevelopmental disorders. Progr Neurobiol 2012, 99:81-91.
34. De novo mutations in epileptic encephalopathies. Nature 2013, 501:217-221. Epi4K Consortium and Epilepsy Phenome/Genome Project.
35. De novo mutations in synaptic transmission genes including DNM1 cause epileptic encephalopathies. Am J Hum Genet 2014, 95:360-370. EuroEPINOMICS-RES Consortium, Epilepsy Phenome/Genome ProjectEpilepsy Phenome/Genome Project, Epi4k ConsortiumEpi4k Consortium.
36. O'Roak BJ, Deriziotis P, Lee C, et al. Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations. Nat Genet 2011, 43:585-589.
37. Sanders SJ, Ercan-Sencicek AG, Hus V, et al. Multiple recurrent de novo CNVs, including duplications of the 7q11.23 Williams syndrome region, are strongly associated with autism. Neuron 2011, 70:863-885.
38. Neale BM, Kou Y, Liu L, et al. Patterns and rates of exonic de novo mutations in autism spectrum disorders. Nature 2012, 485:242-245.
39. Rauch A, Wieczorek D, Graf E, et al. Range of genetic mutations associated with severe non-syndromic sporadic intellectual disability: an exome sequencing study. Lancet 2012, 380:1674-1682.
40. de Ligt J, Willemsen MH, van Bon BW, et al. Diagnostic exome sequencing in persons with severe intellectual disability. N Engl J Med 2012, 367:1921-1929.
41. Nava C, Dalle C, Rastetter A, et al. De novo mutations in HCN1 cause early infantile epileptic encephalopathy. Nat Genet 2014, 46:640-645.
42. Carvill GL, Regan BM, Yendle SC, et al. GRIN2A mutations cause epilepsy-aphasia spectrum disorders. Nat Genet 2013, 45:1073-1076.
43. Endele S, Rosenberger G, Geider K, et al. Mutations in GRIN2A and GRIN2B encoding regulatory subunits of NMDA receptors cause variable neurodevelopmental phenotypes. Nat Genet 2010, 42:1021-1026.
44. Lesca G, Rudolf G, Bruneau N, et al. GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction. Nat Genet 2013, 4:1061-1066.
45. Carvill GL, Weckhuysen S, McMahon JM, et al. GABRA1 and STXBP1: novel genetic causes of Dravet syndrome. Neurology 2014, 82:1245-1253.
46. Nakamura K, Kodera H, Akita T, et al. De novo mutations in GNAO1, encoding a Gαo subunit of heterotrimeric G proteins, cause epileptic encephalopathy. Am J Hum Genet 2013, 93:496-505.
47. Barcia G, Fleming MR, Deligniere A, et al. De novo gain-of-function KCNT1 channel mutations cause malignant migrating partial seizures of infancy. Nat Genet 2012, 44:1255-1259.
48. Ogiwara I, Ito K, Sawaishi Y, et al. De novo mutations of voltage-gated sodium channel alphaII gene SCN2A in intractable epilepsies. Neurology 2009, 73:1046-1053.
49. Ohba C, Kato M, Takahashi S, et al. Early onset epileptic encephalopathy caused by de novo SCN8A mutations. Epilepsia 2014, 55:994-1000.
50. Veeramah KR, O'Brien JE, Meisler MH, et al. De novo pathogenic SCN8A mutation identified by whole-genome sequencing of a family quartet affected by infantile epileptic encephalopathy and SUDEP. Am J Hum Genet 2012, 90:502-510.
51. Kodera H, Nakamura K, Osaka H, et al. De novo mutations in SLC35A2 encoding a UDP-galactose transporter cause early-onset epileptic encephalopathy. Hum Mut 2013, 34:1708-1714.
52. Dhindsa RS, Bradrick SS, Yao X, et al. Epileptic encephalopathy-causing mutations in DNM1 impair synaptic vesicle endocytosis. Neurol Gen 2015, 1:1-9.
53. Gleeson JG, Minnerath S, Kuzniecky RI, et al. Somatic and germline mosaic mutations in the doublecortin gene are associated with variable phenotypes. Am J Hum Genet 2000, 67:574-581.
54. Poduri A, Evrony GD, Cai X, et al. Somatic activation of AKT3 causes hemispheric developmental brain malformations. Neuron 2012, 74:41-48.
55. D'Gama AM, Geng Y, Couto JA, et al. Mammalian target of rapamycin pathway mutations cause hemimegalencephaly and focal cortical dysplasia. Ann Neurol 2015, 77:720-725.
56. Jamuar SS, Lam AT, Kircher M, et al. Somatic mutations in cerebral cortical malformations. N Engl J Med 2014, 371:733-743.
57. Copy number variant analysis from exome data in 349 patients with epileptic encephalopathy. Ann Neurol 2015, 78:323-328. Epilepsy Phenome/Genome Project Epi4K Consortium.
58. Mefford HC, Yendle SC, Hsu C, et al. Rare copy number variants are an important cause of epileptic encephalopathies. Ann Neurol 2011, 70:974-985.
59. Olson H, Shen Y, Avallone J, et al. Copy number variation plays an important role in clinical epilepsy. Ann Neurol 2014, 75:943-958.
60. Dibbens LM, de Vries B, Donatello S, et al. Mutations in DEPDC5 cause familial focal epilepsy with variable foci. Nat Genet 2013, 45:546-551.
61. Ishida S, Picard F, Rudolf G, et al. Mutations of DEPDC5 cause autosomal dominant focal epilepsies. Nat Genet 2013, 45:552-555.
62. Picard F, Makrythanasis P, Navarro V, et al. DEPDC5 mutations in families presenting as autosomal dominant nocturnal frontal lobe epilepsy. Neurology 2014, 82:2101-2106.
63. Thomas RH, Berkovic SF The hidden genetics of epilepsy-a clinically important new paradigm. Nat Rev Neurol 2014, 10:283-292.
64. Petrovski S, Wang Q, Heinzen EL, Allen AS, Goldstein DB Genic intolerance to functional variation and the interpretation of personal genomes. PLoS Genet 2013, 9:e1003709.
65. Samocha KE, Robinson EB, Sanders SJ, et al. A framework for the interpretation of de novo mutation in human disease. Nat Genet 2014, 46:944-950.
66. Zhu X, Petrovski S, Xie P, et al. Whole-exome sequencing in undiagnosed genetic diseases: interpreting 119 trios. Genet Med 2015, published online Jan 15. 10.1038/gim.2014.191.
67. Hynynen J, Komulainen T, Tukiainen E, et al. Acute liver failure after valproate exposure in patients with POLG1 mutations and the prognosis after liver transplantation. Liver Transpl 2014, 20:1402-1412.
68. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004, 428:486.
69. Mikati MA, Jiang Y, Carboni M, et al. Quinidine in the treatment of KCNT1 positive epilepsies. Ann Neurol 2015, in press.
70. Muona M, Berkovic SF, Dibbens LM, et al. A recurrent de novo mutation in KCNC1 causes progressive myoclonus epilepsy. Nat Genet 2015, 47:39-46.
71. Todd E, Gurba KN, Botzolakis EJ, Stanic AK, Macdonald RL GABAA receptor biogenesis is impaired by the gamma2 subunit febrile seizure-associated mutation, GABRG2(R177G). Neurobiol Dis 2014, 69:215-224.
72. Kang JQ, Shen W, Macdonald RL Trafficking-deficient mutant GABRG2 subunit amount may modify epilepsy phenotype. Ann Neurol 2013, 74:547-559.
73. Tian M, Macdonald RL The intronic GABRG2 mutation, IVS6+2T->G, associated with childhood absence epilepsy altered subunit mRNA intron splicing, activated nonsense-mediated decay, and produced a stable truncated gamma2 subunit. J Neurosci 2012, 32:5937-5952.
74. Yuan H, Low CM, Moody OA, Jenkins A, Traynelis SF Ionotropic GABA and glutamate receptor mutations and human neurologic diseases. Mol Pharmacol 2015, 88:203-217.
75. Dyhrfjeld-Johnsen J, Berdichevsky Y, Swiercz W, Sabolek H, Staley KJ Interictal spikes precede ictal discharges in an organotypic hippocampal slice culture model of epileptogenesis. J Clin Neurophysiol 2010, 27:418-424.
76. Hochbaum DR, Zhao Y, Farhi SL, et al. All-optical electrophysiology in mammalian neurons using engineered microbial rhodopsins. Nat Methods 2014, 11:825-833.
77. Lancaster MA, Knoblich JA Generation of cerebral organoids from human pluripotent stem cells. Nat Protoc 2014, 9:2329-2340.
78. Hortopan GA, Dinday MT, Baraban SC Zebrafish as a model for studying genetic aspects of epilepsy. Dis Model Mech 2010, 3:144-148.
79. Williams SN, Locke CJ, Braden AL, Caldwell KA, Caldwell GA Epileptic-like convulsions associated with LIS-1 in the cytoskeletal control of neurotransmitter signaling in Caenorhabditis elegans. Hum Mol Genet 2004, 13:2043-2059.
80. Parker L, Padilla M, Du Y, Dong K, Tanouye MA Drosophila as a model for epilepsy: bss is a gain-of-function mutation in the para sodium channel gene that leads to seizures. Genetics 2011, 187:523-534.
81. Jones NC, O'Brien TJ, Powell KL Morphometric changes and molecular mechanisms in rat models of idiopathic generalized epilepsy with absence seizures. Neurosci Lett 2011, 497:185-193.
82. Paemka L, Mahajan VB, Ehaideb SN, et al. Seizures are regulated by ubiquitin-specific peptidase 9 X-linked (USP9X), a de-ubiquitinase. PLoS Genet 2015, 11:e1005022.
83. Noebels JL Single-gene models of epilepsy. Adv Neurol 1999, 79:227-238.
84. Smith M, Wilcox KS, White HS Discovery of antiepileptic drugs. Neurotherapeutics 2007, 4:12-17.
85. Leite JP, Garcia-Cairasco N, Cavalheiro EA New insights from the use of pilocarpine and kainate models. Epilepsy Res 2002, 50:93-103.
86. Burgess DL, Jones JM, Meisler MH, Noebels JL Mutation of the Ca2+ channel beta subunit gene Cchb4 is associated with ataxia and seizures in the lethargic (lh) mouse. Cell 1997, 88:385-392.
87. Fletcher CF, Lutz CM, O'Sullivan TN, et al. Absence epilepsy in tottering mutant mice is associated with calcium channel defects. Cell 1996, 87:607-617.
88. Boumil RM, Letts VA, Roberts MC, et al. A missense mutation in a highly conserved alternate exon of dynamin-1 causes epilepsy in fitful mice. PLoS Genet 2010, 6:e1001046.
89. Klaassen A, Glykys J, Maguire J, Labarca C, Mody I, Boulter J Seizures and enhanced cortical GABAergic inhibition in two mouse models of human autosomal dominant nocturnal frontal lobe epilepsy. Proc Natl Acad Sci USA 2006, 103:19152-19157.
90. Yu FH, Mantegazza M, Westenbroek RE, et al. Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nat Neurosci 2006, 9:1142-1149.
91. Tan HO, Reid CA, Single FN, et al. Reduced cortical inhibition in a mouse model of familial childhood absence epilepsy. Proc Natl Acad Sci USA 2007, 104:17536-17541.
92. Reid CA, Leaw B, Richards KL, et al. Reduced dendritic arborization and hyperexcitability of pyramidal neurons in a Scn1b-based model of Dravet syndrome. Brain 2014, 137:1701-1715.
93. Baraban SC, Dinday MT, Hortopan GA Drug screening in Scn1a zebrafish mutant identifies clemizole as a potential Dravet syndrome treatment. Nat Commun 2013, 4:2410.
94. Cheng AC, Coleman RG, Smyth KT, et al. Structure-based maximal affinity model predicts small-molecule druggability. Nat Biotech 2007, 25:71-75.
95. King GF Venoms as a platform for human drugs: translating toxins into therapeutics. Expert Opin Biol Ther 2011, 11:1469-1484.
96. Lee JJ, Yokota T Antisense therapy in neurology. J Pers Med 2013, 3:144-176.
97. Meyer K, Ferraiuolo L, Schmelzer L, et al. Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates. Mol Ther 2015, 23:477-487.
98. de Lucas Cerrillo AM, Bond WS, Rex TS Safety and angiogenic effects of systemic gene delivery of a modified erythropoietin. Gene Ther 2015, 22:365-373.
99. Klepper J, Scheffer H, Leiendecker B, et al. Seizure control and acceptance of the ketogenic diet in GLUT1 deficiency syndrome: a 2- to 5-year follow-up of 15 children enrolled prospectively. Neuropediatrics 2005, 36:302-308.
100. van Karnebeek CD, Shevell M, Zschocke J, Moeschler JB, Stockler S The metabolic evaluation of the child with an intellectual developmental disorder: diagnostic algorithm for identification of treatable causes and new digital resource. Mol Gen Metab 2014, 111:428-438.
101. Mills PB, Struys E, Jakobs C, et al. Mutations in antiquitin in individuals with pyridoxine-dependent seizures. Nat Med 2006, 12:307-309.
102. Boutry-Kryza N, Labalme A, Ville D, et al. Molecular characterization of a cohort of 73 patients with infantile spasms syndrome. Eur J Med Genet 2015, 58:51-58.
103. Helbig I, Swinkels ME, Aten E, et al. Structural genomic variation in childhood epilepsies with complex phenotypes. Eur J Hum Genet 2014, 22:896-901.
104. Kodera H, Kato M, Nord AS, et al. Targeted capture and sequencing for detection of mutations causing early onset epileptic encephalopathy. Epilepsia 2013, 54:1262-1269.
105. Carvill GL, Heavin SB, Yendle SC, et al. Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1. Nat Genet 2013, 45:825-830.
106. Poduri A A channel for precision diagnosis and treatment in genetic epilepsy. Ann Neurol 2014, 76:323-324.
107. Milligan CJ, Li M, Gazina EV, et al. KCNT1 gain of function in 2 epilepsy phenotypes is reversed by quinidine. Ann Neurol 2014, 75:581-590.
108. Bearden D, Strong A, Ehnot J, DiGiovine M, Dlugos D, Goldberg EM Targeted treatment of migrating partial seizures of infancy with quinidine. Ann Neurol 2014, 76:457-461.
109. Orhan G, Bock M, Schepers D, et al. Dominant-negative effects of KCNQ2 mutations are associated with epileptic encephalopathy. Ann Neurol 2014, 75:382-394.
110. Pierson TM, Yuan H, Marsh ED, et al. Mutation and early-onset epileptic encephalopathy: personalized therapy with memantine. Ann Clin Transl Neurol 2014, 1:190-198.
111. Yuan H, Hansen KB, Zhang J, et al. Functional analysis of a de novo GRIN2A missense mutation associated with early-onset epileptic encephalopathy. Nat Commun 2014, 5:3251.
112. Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010, 363:1801-1811.
113. Krueger DA, Wilfong AA, Holland-Bouley K, et al. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol 2013, 74:679-687.
114. Parker WE, Orlova KA, Parker WH, et al. Rapamycin prevents seizures after depletion of STRADA in a rare neurodevelopmental disorder. Sci Transl Med 2013, 5:182ra53.